HCQ
HCQ is a pharmaceutical drug with 10 clinical trials. Currently 2 active trials ongoing. Historical success rate of 83.3%.
Success Metrics
Based on 5 completed trials
Phase Distribution
Phase Distribution
1
Early Stage
1
Mid Stage
5
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
71.4%
5 of 7 finished
28.6%
2 ended early
2
trials recruiting
10
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer
Pretreatment With HCQ Before Radiotherapy and Chemotherapy in Advanced NPC Patients
The Clinical Efficacy and Safety of Iguratimod in RA and Early RA Patients for 6 Months Treatment
Prediction of Relapse Risk in Stable Systemic Lupus Erythematosus
Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease
Clinical Trials (10)
Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer
Pretreatment With HCQ Before Radiotherapy and Chemotherapy in Advanced NPC Patients
The Clinical Efficacy and Safety of Iguratimod in RA and Early RA Patients for 6 Months Treatment
Prediction of Relapse Risk in Stable Systemic Lupus Erythematosus
Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease
Evaluation of the Efficacy and Safety of Treatments for Patients Hospitalized for COVID-19 Infection Without Signs of Acute Respiratory Failure, in Tunisia
Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression
Efficacy of Hydroxychloroquine (HCQ) as Post Exposure Prophylaxis (PEP) for Prevention of COVID-19
Combination Therapy Prevents the Relapse of RA
Phase 1-2 Trial HCQ Plus TACE in Unresectable HCC
All 10 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 10